BlueRock and bit.bio sign Treg therapies discovery deal
Drug Discovery World
AUGUST 7, 2023
Bayer subsidiary BlueRock Therapeutics, and bit.bio have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies. Under the terms of the agreement, bit.bio will use its machine learning discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. The agreement also includes options for BlueRock to license bit.bio’s opti-ox precision cell programming technology to control the expression of TF combinations within T
Let's personalize your content